More research is needed to address barriers to therapeutic monitoring of prostate cancer patients on androgen deprivation ...

Discover new insights into testosterone recovery following androgen deprivation therapy in men undergoing radiotherapy for ...

Nonlinear association seen for effective castration period with metastasis-free survival for any ADT duration.

Investigators studied cardiotoxicities of first-line regimens for metastatic hormone-sensitive and nonmetastatic castration-resistant prostate cancer.

The rate at which PSA rises after hormonal therapy for prostate cancer is a key factor in determining the effectiveness of ...

Local radiation therapy appears beneficial for men with bone metastatic hormone-sensitive prostate cancer (mHSPC).

In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen ...

Patients with metastatic prostate cancer may have improved survival outcomes after undergoing next-generation PSMA PET ...

Bayer said on Monday that it has applied to the EU's drugs regulator for the use of Nubeqa, also known as darolutamide, in ...

Bayer is seeking EMA approval for darolutamide in metastatic hormone-sensitive prostate cancer, building on promising Phase ...

Hot flushes in men are sudden, intense heat waves caused by hormone therapy. Learn how to manage them effectively.

Bayer announced the submission of an application to the European Medicines Agency for the oral androgen receptor inhibitor ...